Follow-The-Filings

Security · featured owners

BTAI Bioxcel Therapeutics Inc.

COMMON STOCK Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.0%
  • $2M
  • 1 add

Who owns this now

Largest portfolio weights among featured holders · max 0.0% (Howard Marks - Oaktree Capital Management) · not free-float ownership

  1. Howard Marks add 0.03%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Howard Marks - Oaktree Capital Management 2026 Q2 0.03% Add +472.3% 1,380,248 $2M history

1 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 18 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 1.01,1.03 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 1.01,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 1.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 3.02,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 8.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 6 rows shown

Filed Form Detail Links
4 Period Aug 12, 2026 Filing Doc
4 Period Jun 15, 2026 · 4 forms Filing Doc
4 Period May 4, 2026 · 4 forms Filing Doc
4 Period May 1, 2026 · 4 forms Filing Doc
4 Period Mar 14, 2026 · 4 forms Filing Doc
4 Period Jan 9, 2026 · 5 forms Filing Doc

Updated 1 day ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.38M $2.27M $0.642M
Gross profit * $120,000 $123,000 $478,000
Gross margin * 8.7% 5.4% 74.5%
Net income -$179.05M -$59.6M -$69.9M
Net margin * -12974.9% -2630.1% -10887.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $72.14M $37.39M $44.68M
Total non-current assets * $1.56M $0.944M $0.231M
Total assets $73.7M $38.34M $44.92M
Total current liabilities $27.27M $22.23M $53.93M
Total non-current liabilities * $102.94M $109.21M $86.45M
Total equity -$56.51M -$93.1M -$95.46M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$155.01M -$72.03M -$57.62M
Cash from investing -$20,000 — $0.00
Cash from financing $26.52M $36.66M $56.52M
Net change in cash -$128.5M -$35.37M -$1.1M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders